Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Complete Research Database
CagriSema Phase III
View StudyCagrilintide-Semaglutide Combination for Weight Management
PRIMARY RESULTS
22.7% weight loss with combination vs 12.1% monotherapy
KEY FINDINGS
- •Superior efficacy vs either component alone
- •Synergistic amylin-GLP1 pathway activation
- •Favorable tolerability profile maintained
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.